Ww International, Inc. (WW) · Nov 5, 2026 · Earnings

WW International earnings beat as clinical growth offsets shrinking core

Beat — Revenue $152.9M vs ~$152.3M consensus; FY EBITDA midpoint raised to $112.5M

WW International’s Q3 earnings narrowly beat revenue expectations, with clinical subscribers and margins improving while the legacy behavioral business continued to contract.

WW is in the middle of a post-bankruptcy business transition: it is shifting from a shrinking traditional behavioral subscription model toward an integrated weight-health platform built around clinical care, GLP-1 access, and higher-value memberships. Its own prior disclosures acknowledged that Clinical growth had not yet offset Behavioral declines.

The quarter modestly cleared the financial bar. Revenue was $152.9 million, narrowly above the published consensus of roughly $152.3 million, while GAAP EPS was $1.51 versus an external estimate near $0.63; the cleaner signal is that full-year Adjusted EBITDA guidance moved up at the midpoint rather than merely being repeated. The revenue beat is small, so this is an execution win, not a decisive turnaround.

FigureQ3 2026Q3 2025Consensus / prior guide
Revenue (Financial Highlights)$152.9M (-11%)$172.1M~$152.3M
Clinical subscription revenue (Q3 Business Updates)$38.0M (+48%)$25.8M
Behavioral subscription revenue (Selected Financial Data)$113.9M (-21.5%)$145.2M
Adjusted EBITDA (Financial Highlights)$51.7M (+21%)$42.8M
Net income (Income Statement)$15.1M$(57.5M)
End-of-period subscribers (Operational Statistics)2.296M (-23.1%)2.986M
FY revenue guidance (Fiscal 2026 Guidance)$625M–$630M$620M–$635M
FY Adjusted EBITDA guidance (Fiscal 2026 Guidance)$110M–$115M$105M–$115M

The strategic pivot is working, but it is not yet large enough to reverse the top line. Clinical subscription revenue rose 48% to $38.0 million and Clinical subscribers increased 40% to 174,000, while Core+ subscribers rose 16% to 546,000. But Behavioral subscription revenue fell 21.5%, and total subscribers declined 23.1%; the new businesses are improving mix and monetization rather than replacing the lost legacy volume today. 〔0〕

Profitability improved mainly through mix and spending control. Adjusted EBITDA rose 21% to $51.7 million and the company produced positive GAAP net income, helped by lower marketing and corporate spending. However, adjusted gross margin slipped to 74.6% from 75.1%, so the earnings improvement reflects cost discipline and a richer clinical mix more than broad-based operating leverage.

The outlook is a small step up, not a reset. Revenue guidance was narrowed around a slightly higher midpoint, while the Adjusted EBITDA midpoint increased from $110 million to $112.5 million. That supports the view that management is executing better than feared, but the range still implies a business relying on margin discipline while legacy demand remains under pressure.

Bottom line: WW is showing credible progress in Clinical, Core+, and cash earnings, and the raised EBITDA midpoint edges the quarter ahead of expectations. The business is improving its mix faster than it is replacing lost behavioral subscribers, so this strengthens the transition story without rewriting it.

What to watch next

Q4 and full-year 2026 results

Original filing on SEC EDGAR

WW International earnings beat as clinical growth offsets shrinking core | WW Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.